Evidence map›Paper›PMID 25717031›Full record

ArticleOncotarget2015

eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.

Oshrat Attar-Schneider, Metsada Pasmanik-Chor, Shelly Tartakover-Matalon, Liat Drucker, Michael Lishner

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Oshrat Attar-SchneiderOncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel.
Metsada Pasmanik-ChorBioinformatics Unit, G.S.W. Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Shelly Tartakover-MatalonOncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel.
Liat DruckerOncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel.
Michael LishnerOncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel.
Meir Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating data indicate translation plays a role in cancer biology, particularly its rate limiting stage of initiation. Despite this evolving recognition, the function and importance of specific translation initiation factors is unresolved. The eukaryotic translation initiation complex eIF4F consists of eIF4E and eIF4G at a 1:1 ratio. Although it is expected that they display interdependent functions, several publications suggest independent mechanisms. This study is the first to directly assess the relative contribution of eIF4F components to the expressed cellular proteome, transcription factors, microRNAs, and phenotype in a malignancy known for extensive protein synthesis-multiple myeloma (MM). Previously, we have shown that eIF4E/eIF4GI attenuation (siRNA/Avastin) deleteriously affected MM cells' fate and reduced levels of eIF4E/eIF4GI established targets. Here, we demonstrated that eIF4E/eIF4GI indeed have individual influences on cell proteome. We used an objective, high throughput assay of mRNA microarrays to examine the significance of eIF4E/eIF4GI silencing to several cellular facets such as transcription factors, microRNAs and phenotype. We showed different imprints for eIF4E and eIF4GI in all assayed aspects. These results promote our understanding of the relative contribution and importance of eIF4E and eIF4GI to the malignant phenotype and shed light on their function in eIF4F translation initiation complex.

Indexed as

Cell Line, TumorEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansImmunoblottingMultiple MyelomaOligonucleotide Array Sequence AnalysisProtein BiosynthesisProteomeReverse Transcriptase Polymerase Chain ReactionRNA, Small InterferingSignal TransductionTransfectionEIF4G1 protein, humanEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GProteomeRNA, Small Interfering

Identifiers

PMID25717031
PMCPMC4414192
OpenAlexW1480737773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.